胃肠道错构瘤性息肉病综合征的癌症风险诊断与管理:美国多学会结直肠癌工作组建议
美国多学会结直肠癌工作组发布共识,总结胃肠道错构瘤性息肉病综合征的临床特征与文献,为诊断、评估和内镜管理提供指导。该类综合征罕见且为常染色体显性遗传,管理重点为预防息肉所致小肠出血和机械性梗阻,并监测癌症风险器官。
要点
- 错构瘤性息肉病综合征罕见且为常染色体显性遗传,与肠道及肠外良恶性肿瘤风险增加相关。
- 诊断基于临床标准,部分病例需证实存在胚系致病性变异。
- 管理重点为预防息肉所致小肠出血和机械性梗阻,并监测癌症风险器官。
核心结论
- 美国多学会结直肠癌工作组共识总结错构瘤性息肉病综合征的临床特征,评估现有文献,并为诊断、评估和管理提供指导,重点在内镜管理。
研究设计与样本
- 美国多学会结直肠癌工作组制定的共识声明,基于文献评估和专家共识。
主要发现
- 错构瘤性息肉病综合征包括Peutz-Jeghers综合征、幼年性息肉病综合征、PTEN错构瘤肿瘤综合征(含Cowden综合征和Bannayan-Riley-Ruvalcaba综合征)及遗传性混合性息肉病综合征。
- Peutz-Jeghers综合征由STK11基因胚系致病性变异所致,是该类综合征中认识最充分的一种。
- 幼年性息肉病综合征由SMAD4或BMPR1A基因胚系致病性变异所致,两者临床病程不同。
- SMAD4致病性变异患者可能出现大量胃息肉病,导致胃肠道出血和/或蛋白丢失性胃病。
- SMAD4突变患者常同时发生遗传性出血性毛细血管扩张症(幼年性息肉病综合征-遗传性出血性毛细血管扩张症重叠综合征),可导致鼻出血、皮肤黏膜毛细血管扩张所致胃肠道出血及动静脉畸形。
关键数值与推荐
- 诊断基于临床标准,部分病例需证实存在胚系致病性变异。
- PTEN基因胚系致病性变异导致重叠临床表型(PTEN错构瘤肿瘤综合征),包括Cowden综合征及相关疾病,与胃肠道和结肠息肉病、结肠癌及其他肠外表现和癌症风险增加相关。
临床怎么用
- 管理重点为预防息肉所致小肠出血和机械性梗阻,并监测癌症风险器官。
- 由于错构瘤性息肉病综合征相对罕见,管理建议基于少量研究。
局限性
- 由于错构瘤性息肉病综合征相对罕见,管理建议基于少量研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis syndrome, the PTEN hamartoma tumor syndrome (including Cowden's syndrome and Bannayan-Riley-Ruvalcaba syndrome), and hereditary mixed polyposis syndrome. Diagnoses are based on clinical criteria and, in some cases, confirmed by demonstrating the presence of a germline pathogenic variant. The best understood hamartomatous polyposis syndrome is Peutz-Jeghers syndrome, caused by germline pathogenic variants in the STK11 gene. The management is focused on prevention of bleeding and mechanical obstruction of the small bowel by polyps and surveillance of organs at increased risk for cancer. Juvenile polyposis syndrome is caused by a germline pathogenic variant in either the SMAD4 or BMPR1A genes, with differing clinical courses. Patients with SMAD4 pathogenic variants may have massive gastric polyposis, which can result in gastrointestinal bleeding and/or protein-losing gastropathy. Patients with SMAD4 mutations usually have the simultaneous occurrence of hereditary hemorrhagic telangiectasia (juvenile polyposis syndrome-hereditary hemorrhagic telangiectasia overlap syndrome) that can result in epistaxis, gastrointestinal bleeding from mucocutaneous telangiectasias, and arteriovenous malformations. Germline pathogenic variants in the PTEN gene cause overlapping clinical phenotypes (known as the PTEN hamartoma tumor syndromes), including Cowden's syndrome and related disorders that are associated with an increased risk of gastrointestinal and colonic polyposis, colon cancer, and other extraintestinal manifestations and cancers. Due to the relative rarity of the hamartomatous polyposis syndromes, recommendations for management are based on few studies. This U.S. Multi-Society Task Force on Colorectal Cancer consensus statement summarizes the clinical features, assesses the current literature, and provides guidance for diagnosis, assessment, and management of patients with the hamartomatous polyposis syndromes, with a focus on endoscopic management.
引用
- Boland CR, Idos GE, Durno C, et al. Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2022. PMID: 35487765. doi:10.1016/j.gie.2022.02.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。